Tags

Type your tag names separated by a space and hit enter

[Prevention of recurrent hemorrhage in patients with cirrhosis. Results of a controlled trial of propranolol versus endoscopic sclerotherapy].
Gastroenterol Clin Biol. 1991; 15(11):833-7.GC

Abstract

Between July 1984 and March 1986, we conducted a prospective randomized trial comparing propranolol and endoscopic sclerotherapy in the prevention of recurrent variceal hemorrhage in a group of non selected alcoholic cirrhotics. Seventy-six patients with variceal hemorrhage were randomized to receive propranolol (P) (34 patients), or sclerotherapy (S) (42 patients) approximately 12 days after initial bleeding. The 2 groups were similar as concern age, sex, etiology of cirrhosis, severity of liver failure, the number of previous hemorrhages, and the severity of initial hemorrhage. No side effects were observed in the P group; 20 patients (48 percent) in the group S had at least one side effect although minor. After an average follow-up of 36 months, 18 patients in group P (53 percent) and 23 in group S (55 percent) had hemorrhagic recurrence. Rebleeding occurred from other sources than esophageal varices in 5 patients, in the group S only. Five patients in group P and 8 patients in group S died of rebleeding. During the follow-up period, 8 patients in group P (23 percent) and 13 patients in group S (31 percent) died. No significant difference could be demonstrated between the 2 groups as regards the percentages of patients without variceal rebleeding or survival, calculated according to the Kaplan Meier method. In conclusion, in this trial, no significant difference could be demonstrated between propranolol and endoscopic sclerosis in the prevention of recurrent variceal hemorrhage in alcoholic cirrhotic patients.

Authors+Show Affiliations

Service d'Hépato-Gastroentérologie, Hôtel-Dieu, Nantes.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
English Abstract
Journal Article
Randomized Controlled Trial

Language

fre

PubMed ID

1769473

Citation

Martin, T, et al. "[Prevention of Recurrent Hemorrhage in Patients With Cirrhosis. Results of a Controlled Trial of Propranolol Versus Endoscopic Sclerotherapy]." Gastroenterologie Clinique Et Biologique, vol. 15, no. 11, 1991, pp. 833-7.
Martin T, Taupignon A, Lavignolle A, et al. [Prevention of recurrent hemorrhage in patients with cirrhosis. Results of a controlled trial of propranolol versus endoscopic sclerotherapy]. Gastroenterol Clin Biol. 1991;15(11):833-7.
Martin, T., Taupignon, A., Lavignolle, A., Perrin, D., & Le Bodic, L. (1991). [Prevention of recurrent hemorrhage in patients with cirrhosis. Results of a controlled trial of propranolol versus endoscopic sclerotherapy]. Gastroenterologie Clinique Et Biologique, 15(11), 833-7.
Martin T, et al. [Prevention of Recurrent Hemorrhage in Patients With Cirrhosis. Results of a Controlled Trial of Propranolol Versus Endoscopic Sclerotherapy]. Gastroenterol Clin Biol. 1991;15(11):833-7. PubMed PMID: 1769473.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Prevention of recurrent hemorrhage in patients with cirrhosis. Results of a controlled trial of propranolol versus endoscopic sclerotherapy]. AU - Martin,T, AU - Taupignon,A, AU - Lavignolle,A, AU - Perrin,D, AU - Le Bodic,L, PY - 1991/1/1/pubmed PY - 1991/1/1/medline PY - 1991/1/1/entrez SP - 833 EP - 7 JF - Gastroenterologie clinique et biologique JO - Gastroenterol Clin Biol VL - 15 IS - 11 N2 - Between July 1984 and March 1986, we conducted a prospective randomized trial comparing propranolol and endoscopic sclerotherapy in the prevention of recurrent variceal hemorrhage in a group of non selected alcoholic cirrhotics. Seventy-six patients with variceal hemorrhage were randomized to receive propranolol (P) (34 patients), or sclerotherapy (S) (42 patients) approximately 12 days after initial bleeding. The 2 groups were similar as concern age, sex, etiology of cirrhosis, severity of liver failure, the number of previous hemorrhages, and the severity of initial hemorrhage. No side effects were observed in the P group; 20 patients (48 percent) in the group S had at least one side effect although minor. After an average follow-up of 36 months, 18 patients in group P (53 percent) and 23 in group S (55 percent) had hemorrhagic recurrence. Rebleeding occurred from other sources than esophageal varices in 5 patients, in the group S only. Five patients in group P and 8 patients in group S died of rebleeding. During the follow-up period, 8 patients in group P (23 percent) and 13 patients in group S (31 percent) died. No significant difference could be demonstrated between the 2 groups as regards the percentages of patients without variceal rebleeding or survival, calculated according to the Kaplan Meier method. In conclusion, in this trial, no significant difference could be demonstrated between propranolol and endoscopic sclerosis in the prevention of recurrent variceal hemorrhage in alcoholic cirrhotic patients. SN - 0399-8320 UR - https://www.unboundmedicine.com/medline/citation/1769473/[Prevention_of_recurrent_hemorrhage_in_patients_with_cirrhosis__Results_of_a_controlled_trial_of_propranolol_versus_endoscopic_sclerotherapy]_ L2 - https://medlineplus.gov/cirrhosis.html DB - PRIME DP - Unbound Medicine ER -